Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of a single dose and chronic exposure to celecoxib or rofecoxib on the transcriptome of mouse aorta

ABSTRACT: Effect of a single dose and chronic exposure to celecoxib or rofecoxib on the transcriptome of mouse aorta

PROVIDER: PRJNA380608 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5320440_1.fastq.gz	Fastqsanger.gz
	SRR5320440_2.fastq.gz	Fastqsanger.gz
	SRR5320450_1.fastq.gz	Fastqsanger.gz
	SRR5320450_2.fastq.gz	Fastqsanger.gz
	SRR5320441_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 92

Similar Datasets

Celecoxib, Rofecoxib Gavage Treated Mice, Aorta RNA-Seq

Project description:Celecoxib, Rofecoxib Gavage Treated Mice, Aorta RNA-Seq

2020-03-07 | GSE97066 | GEO

Celecoxib, Rofecoxib Chronically Treated Mice, Aorta RNA-Seq

Project description:Celecoxib, Rofecoxib Chronically Treated Mice, Aorta RNA-Seq

2020-03-07 | GSE95802 | GEO

Celecoxib, Rofecoxib Chronically Treated Mice, with IL1beta, Aorta RNA-Seq

Project description:We screen for vascular off-target effects at therapeutic concentrations of celecoxib and rofecoxib using genomic approaches in a mouse model of vascular inflammatory responses. We assess whether therapeutic concentrations of celecoxib and rofecoxib might elicit distinct genomic effects in vivo in mice by comprehensive and unbiased analysis of the whole transcriptome sequencing. Drug specific differences in their expression profiles would be indicative of off-target effects.

2020-02-28 | GSE95500 | GEO

Celecoxib, rofecoxib treated human smooth muscle cells microarray timecourse

Project description:The aim of this data set is to measure the effect of rofecoxib and celecoxib on the transcription profile in an in vitro inflammation model. Transcription profiling was carried out using Affymetrix HG U-133A v2 microarrays. Human aortic smooth muscle cells (3F1243) were pre-treated with rofecoxib (500 nM) or celecoxib (500 nM) for two hours and subsequently exposed to IL-1beta (10 ng/ml). Transcription profiling was carried out at several time points of IL-1beta exposure: Four samples at -2 hours. Four samples each of control, celecoxib, and rofecoxib at each time point 0hr, 2hr, 8hr and 24hr. 52 samples in total.

2015-04-20 | E-GEOD-59671 | biostudies-arrayexpress

Celecoxib, rofecoxib treated human smooth muscle cells microarray timecourse

2015-04-20 | GSE59671 | GEO

Mus musculus

Project description:Celecoxib, Rofecoxib Gavage Treated Mice, Aorta RNA-Seq

| PRJNA380614 | ENA

Mus musculus

Project description:Celecoxib, Rofecoxib Chronically Treated Mice, Aorta RNA-Seq

| PRJNA378478 | ENA

mRNA sequencing of rat hearts treated chronically with rofecoxib or its vehicle

Project description:We reported previously that chronic treatment with the Cyclooxygenase-2 inhibitor, rofecoxib, increased acute mortality in rats exposed to ischemia/reperfusion injury (I/R). This manifestation of hidden cardiotoxicity was attributed to the proarrhythmic effect of the drug on the ischemic heart. However, rofecoxib also had beneficial effects on ischemic injury, manifesting as decreased infarct size. In the present study, we aimed to identify molecular changes caused by chronic rofecoxib treatment in the heart. Rats were treated with 5.12 mg/kg rofecoxib or its vehicle for four weeks. Messenger RNA (mRNA), microRNA (miRNA) deep sequencing data, and proteomic datasets of left ventricular tissue samples were used for an unbiased differential expression analysis followed by in silico molecular network analysis and experimental target validation. Using mass spectrometry and filtering criteria, 26 proteins were identified that exhibited pronounced changes in protein expression or phosphorylation due to chronic rofecoxib treatment. The transcriptomic analysis showed mild alterations in the heart´s mRNA- and miRNA expression. The posttranscriptional regulation of mRNAs by miRNAs did not result in differential protein expression. This is the first demonstration that chronic rofecoxib treatment affects posttranslational modification and expression of several proteins in the heart. These are potential off-target effects that could account for the hidden cardiotoxic and/or cardioprotective effects of rofecoxib.

2024-10-30 | E-MTAB-13913 | biostudies-arrayexpress

miRNA sequencing of rat hearts treated chronically with rofecoxib or its vehicle

2024-10-30 | E-MTAB-13909 | biostudies-arrayexpress

Expression data from mouse aorta with chronic intermittent hypoxia exposure

Project description:Expression data from mouse aorta with chronic intermittent hypoxia exposure

| PRJNA606452 | ENA